The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
== Wear == The effect of wear on a roller chain is to increase the pitch (spacing of the links), causing the chain to grow longer. Note that this is due to wear at the pivoting pins and bushes, not from actual stretching of the metal (as does happen to some flexible steel components such as the hand-brake cable of a motor vehicle). With modern chains it is unusual for a chain (other than that of a bicycle) to wear until it breaks, since a worn chain leads to the rapid onset of wear on the teeth of the sprockets, with ultimate failure being the loss of all the teeth on the sprocket. The sprockets (in particular the smaller of the two) suffer a grinding motion that puts a characteristic hook shape into the driven face of the teeth. (This effect is made worse by a chain improperly tensioned, but is unavoidable no matter what care is taken). The worn teeth (and chain) no longer provides smooth transmission of power and this may become evident from the noise, the vibration or (in car engines using a timing chain) the variation in ignition timing seen with a timing light. Both sprockets and chain should be replaced in these cases, since a new chain on worn sprockets will not last long. However, in less severe cases it may be possible to save the larger of the two sprockets, since it is always the smaller one that suffers the most wear. Only in very light-weight applications such as a bicycle, or in extreme cases of improper tension, will the chain normally jump off the sprockets. The lengthening due to wear of a chain is calculated by the following formula:
=== Recent === Flat-screen display technology began in the 2000s, replacing the cathode-ray tube displays of the previous century. In the years that followed, technology evolved and displays became increasingly thinner, higher in resolution and larger. As a result, the required composite structures become increasingly complex, and the manufacturing methods became more demanding. Edwards Vacuum is involved in flat-screen display production with its turbomolecular pumps, which enable the high levels of vacuum required for the production process and coating of these displays. Abatement installations remove global warming, toxic, pyrophoric, and corrosive gases in a safe, regulatory way. Vacuum coating is used in other industries, including solar cell photovoltaics. They are produced with processes such as crystalline silicon, CdTe, CIGS, or Silicon Thin Film Technology, all of which require vacuum. Lithium-ion batteries are a rapidly growing market, that also requires large amounts of vacuum in various stages of their production. Edwards CTI-Cryogenics and Edwards Polycold cryopumps and cryochillers play their role in cryogenic fields: MRI machines that uses liquid helium and require cryogenic cooling, storage of large quantities of food, freezing of blood and tissues samples, and semiconductors, as their technology and structures become more complex.
=== Time and frequency === Government standard frequency and time signal services operate time radio stations which continuously broadcast extremely accurate time signals produced by atomic clocks, as a reference to synchronize other clocks. Examples are BPC, DCF77, JJY, MSF, RTZ, TDF, WWV, and YVTO. One use is in radio clocks and watches, which include an automated receiver that periodically (usually weekly) receives and decodes the time signal and resets the watch's internal quartz clock to the correct time, thus allowing a small watch or desk clock to have the same accuracy as an atomic clock. Government time stations are declining in number because GPS satellites and the Internet Network Time Protocol (NTP) provide equally accurate time standards.
Sources: en.wikipedia.org
== Release == To promote Half-Life, Valve's chief marketing officer, Monica Harrington, promoted Valve's reputation in the industry, with conference talks about their advances in game development, leading to coverage in the Wall Street Journal. Half-Life was released on November 19, 1998. When Sierra told Valve it was not planning to promote it beyond launch, Harrington threatened that Valve would "walk away from our agreement and tell the industry that had fallen in love with Valve how screwed up Sierra really was". In response, Sierra reissued Half-Life in a "Game of the Year" edition, boosting sales. In 2001, after renegotiating with Sierra, Valve gained the Half-Life intellectual property and online distribution rights for its games. Valve released two Half-Life demos. The first, Half-Life: Day One, contained the first fifth of the game and was distributed with certain graphic cards. The second, Half-Life: Uplink, was released on February 12, 1999, and featured original content. A short film based on Half-Life, also titled Half-Life: Uplink, was developed by Cruise Control, a British marketing agency, and released on February 11. The protagonist is a journalist who infiltrates the Black Mesa Research Facility, trying to discover what has happened there. Half-Life was censored in Germany to comply with the Federal Department for Media Harmful to Young Persons, which regulates depictions of violence against humans. Valve replaced the human characters with robots, spilling oil and gears instead of blood and body parts when killed, among other changes.
== Actinide partitioning: complexation mechanism == The selective separation of actinides from the PUREX raffinate by advanced processes needs new extracting agents, which must possess a more pronounced affinity towards actinides over lanthanides and other products mostly present in the acidic fuel dissolution. The design and the synthesis of efficient extracting agents rely on a deep knowledge of the complexation mechanism involved in the extraction process. Moreover, the structure and the stability of the ligand complexes with An(III) and Ln(III) upon extraction process, and the ligand selectivity need to be investigated. Research is being devoted to design more N-donor extracting agents, which show promising selectivity towards actinides.
The plant would be capable of converting natural gas into a liquid form that can be trucked to consumers. The project will create between 700 and 2,800 jobs in the region. In May 2019, Minister McNaughton announced that the Ontario government "committed up to $63.7 million" to Southwestern Integrated Fibre Technology (SWIFT) with support from other levels of government. The not-for-profit, publicly-funded SWIFT project to develop a regional fibre optic network, has been one of the key initiatives of the Western Ontario Wardens' Caucus (WOWC) representing upper-tier municipalities in southern Ontario from Dufferin to Windsor. Through SWIFT, federal, provincial and local municipalities "subsidize the construction of an open-access, high-speed broadband network in Southwestern Ontario, Caledon and the Niagara Region." In December 2025, Ford and Niagara Falls mayor Jim Diodati announced a new tourism strategy for the city, including expanded transportation and entertainment offerings such as new "attractions, gaming, wine and restaurants, and arts and culture." In early 2026, Ford announced plans to build a new 2-million square foot convention centre in Toronto, replacing the Metro Toronto Convention Centre. He later also announced plans to take control of the Billy Bishop Toronto City Airport to expand its runway and allow jets at the island airport, a suggestion immediately supported by the Toronto Port Authority. Expansion remains opposed by local Councillors, local community associations and the "NoJetsTo" and "Parks Not Planes" advocacy groups.
As of 2025, GeneDx has contributed to more than 1,100 peer-reviewed publications and contributes to more than 500 validated gene-disease associations through the GeneMatcher platform. In 2026, GeneDx researchers published a validation study in Human Genetics describing Multiscore, an AI-powered gene prioritization tool, that combines machine learning with real-world clinical data from the GeneDx database alongside published literature and OMIM, correctly prioritized the causative gene within the top 10 candidates in 83.5% of cases, outperforming existing phenotype-based prioritization tools including Phrank and LIRICAL. A 2026 real-world health economics analysis (SAVES-Kids), presented at the American College of Medical Genetics (ACMG) annual meeting, found GeneDx's exome and genome sequencing reduced total healthcare costs by up to 61% in the 12 months following testing for children with neurodevelopmental disorders. For children with epilepsy, that represents an average of approximately $80,000 per patient per year.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.